The safety of rosiglitazone in the treatment of Type 2 diabetes

被引：4

作者：

Singh, Sonal ^{[1
,3
]}

Loke, Yoon K. ^{[2
]}

机构：

[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Winston Salem, NC 27103 USA

[2] Univ E Anglia, Sch Med, Norwich NR4 7TJ, Norfolk, England

[3] Wake Forest Univ, Bowman Gray Sch Med, Gen Internal Med Sect, Winston Salem, NC 27157 USA

来源：

EXPERT OPINION ON DRUG SAFETY | 2008年 / 7卷 / 05期

关键词：

cardiovascular adverse effects; fractures; heart failure; myocardial infarction; rosiglitazone; safety;

D O I：

10.1517/14740338.7.5.579

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease. Objectives: To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone. Methods: Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers. Conclusion: Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.

引用

页码：579 / 585

页数：7

共 44 条

[1]

[Anonymous], GLAXOSMITHKLINE CLIN

[2] Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women [J].

Berberoglu, Zehra ;

Gursoy, Alptekin ;

Bayraktar, Nilufer ;

Yazici, Ayse Canan ;

Tutuncu, Neslihan Bascil ;

Demirag, Nilgun Guvener .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (09) :3523-3530

[3] Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus [J].

Berria, R. ;

Glass, L. ;

Mahankali, A. ;

Miyazaki, Y. ;

Monroy, A. ;

De Filippis, E. ;

Cusi, K. ;

Cersosimo, E. ;

DeFronzo, R. A. ;

Gastaldelli, A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (03) :275-281

[4] Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes Mellitus [J].

Bolen, Shari ;

Feldman, Leonard ;

Vassy, Jason ;

Wilson, Lisa ;

Yeh, Hsin-Chieh ;

Marinopoulos, Spyriclon ;

Wiley, Crystal ;

Selvin, Elizabeth ;

Wilson, Renee ;

Bass, Eric B. ;

Brancati, Frederick L. .

ANNALS OF INTERNAL MEDICINE, 2007, 147 (06) :386-399

[5] A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors [J].

Chiquette, E ;

Ramirez, G ;

DeFronzo, R .

ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (19) :2097-2104

[6] Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia [J].

Deeg, Mark A. ;

Buse, John B. ;

Goldberg, Ronald B. ;

Kendall, David M. ;

Zagar, Anthony J. ;

Jacober, Scott J. ;

Khan, Mehmood A. ;

Perez, Alfonzo T. ;

Tan, Meng H. .

DIABETES CARE, 2007, 30 (10) :2458-2464

[7] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[8]

*EMEA, 2007, EPRS AUTH MED PROD H

[9] Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure [J].

Erdmann, Erland ;

Wilcox, Robert G. .

EUROPEAN HEART JOURNAL, 2008, 29 (01) :12-20

[10] Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review [J].

Eurich, Dean T. ;

McAlister, Finlay A. ;

Blackburn, David F. ;

Majumdar, Sumit R. ;

Tsuyuki, Ross T. ;

Varney, Janice ;

Johnson, Jeffrey A. .

BMJ-BRITISH MEDICAL JOURNAL, 2007, 335 (7618) :497-501

← 1 2 3 4 5 →